The Limited Times

Now you can see non-English news...

Covid-19: due to unexplained excess mortality, a drug trial suspended in France

2020-10-29T21:17:48.433Z


The anakinra had given "encouraging" results for severe forms of Covid-19 disease.About thirty patients are concerned. The ANSM drug agency announces that it has requested the suspension of a clinical trial in France evaluating the drug anakinra in the treatment of Covid-19. A decision that follows unexplained excess mortality among treated patients, revealed by preliminary results of the trial. This drug, anakinra (trade name: Kineret), initially intended for rheumatic diseas


About thirty patients are concerned.

The ANSM drug agency announces that it has requested the suspension of a clinical trial in France evaluating the drug anakinra in the treatment of Covid-19.

A decision that follows unexplained excess mortality among treated patients, revealed by preliminary results of the trial.

This drug, anakinra (trade name: Kineret), initially intended for rheumatic diseases, had given "encouraging" results for severe forms of Covid-19 disease by significantly reducing the risk of death and the need for 'be put on a ventilator in intensive care, according to a study by a French medical team from the Paris Saint-Joseph Hospital Group (GHPSJ), published in the specialized journal The Lancet Rheumatology.

Treatment that can be continued

This safety information does not call into question the benefit / risk ratio of anakinra when it is used in the validated indications of its marketing authorization (AMM) such as for example for rheumatoid arthritis, underlines the ANSM. .

"Patients treated for one of these pathologies can therefore continue their treatment".

"If symptoms suggestive of Covid-19 appear", the health agency invites them to consult their doctor.

READ ALSO>

Covid-19: five questions on anakinra, a drug with "obvious" effects


The ANACONDA-COVID-19 trial conducted by the Tours University Hospital involves around thirty patients.

The interim review of data showed early excess mortality in the group of patients treated with anakinra compared to the group who did not receive this drug.

"A deleterious effect of anakinra cannot be excluded insofar as the information available at this stage does not allow this difference to be explained" between these two groups of patients, notes the ANSM.

To counter acute respiratory distress syndrome

Anakinra targets, to block it, one of the cytokines, interleukin-1 (IL-1) involved in the "inflammatory storm" which results in acute respiratory distress syndrome (ARDS) requiring the assistance of a physician. artificial ventilation with the use of respirator.

The other clinical trials with anakinra authorized in France in the Covid-19 indication are also suspended.

These clinical trials were however already stopped or had not yet started, specifies the health agency.

Finally, the ANSM "reminds health professionals that at present, no study shows the interest of its use in the care of Covid patients".

Source: leparis

All life articles on 2020-10-29

You may like

News/Politics 2024-02-01T10:20:10.271Z
Life/Entertain 2024-03-01T08:04:15.518Z

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.